Iantrek raises $23M for MIGS
- Iantrek’s $23 million Series B was an August 30, 2022 financing — not new today — to push its glaucoma surgery devices into U.S. rollout. - The key detail was pathway coverage: Iantrek said it had FDA-registered technologies for both trabecular and suprachoroidal outflow, with first U.S. suprachoroidal cases already done. - Why it matters now: that 2022 raise helped set up Iantrek’s later 2025 Series C and commercial launch push around AlloFlo Uveo.
Glaucoma surgery is one of those markets where a small device tweak can matter a lot. Lowering eye pressure is the whole game, but surgeons have had a limited set of minimally invasive tools, and most of them work through the same drainage route. That is the gap Iantrek was trying to hit. The company’s much-cited $23 million raise did happen — but it happened on August 30, 2022, not this week — and the money was meant to move its MIGS platform into U.S. clinical introduction and post-marketing studies. (biospace.com) ### What is MIGS, exactly? MIGS means minimally invasive glaucoma surgery — small-footprint procedures meant to lower intraocular pressure with less tissue disruption than older filtering surgeries. The appeal is obvious: safer workflow, faster recovery, and easier pairing with cataract surgery. But the category has also been crowded around a narrow idea of how fluid should leave the eye. (biospace.com) ### What was Iantrek trying to do differently? The company’s pitch was pathway diversification. In 2022, Iantrek said it was the only MIGS company with FDA-registered technologies aimed at both of the eye’s natural aqueous outflow pathways — trabecular and suprachoroidal. Basically, instead of betting on one plumbing ro(biospace.com)up being. (biospace.com) ### Why did the suprachoroidal angle matter so much? Because that pathway had promise but baggage. Iantrek’s 2022 materials centered on CycloPen, a micro-interventional system targeting suprachoroidal outflow. The company argued that this route was already an established therapeutic target and pointed to prior MIGS expe(biospace.com)uld stick. (biospace.com) ### What actually happened in that financing? Iantrek closed an oversubscribed $23 million Series B led by Visionary Ventures and Sectoral Asset Management. The round also brought Marc-Andre Marcotte of Sectoral and Farrell Tyson of Visionary onto the board. At the same time, Iantrek said the first U.S. cases using its (biospace.com)ical use. (biospace.com) ### Was this just an old press-release story? Turns out it became a real bridge to later commercialization. By 2025, Iantrek had raised a larger $42 million Series C to fund the U.S. commercial launch of AlloFlo Uveo, which it described as a first-of-its-kind surgical solution targeting the uveoscleral pathway. Its own site now points to commercialization, seven peer-reviewed studies, and thousands of U.S. procedures as signs that the platform moved beyond concept. (biospace.com) ### So why does this story still matter? Because the 2022 round marks the moment Iantrek stopped being just an ophthalmic device idea and started building a market position around “total-outflow enhancement.” That phrase is basically the strategy in one line — offer surgeons more than one drainage-pathway option, then turn that into a product family instead of a single gadget. (iantrekmed.com) ### What should readers take away? The clean read is this: the $23 million raise is old news, but it was an important inflection point. It funded Iantrek’s move from development into U.S. use, helped validate a suprachoroidal MIGS approach, and set up the bigger 2025 launch-and-expansion phase that followed. (biospace.com)
